Q2 & H1 FY27 Results Approved; Dividend Paid, ESOP Allotment, 85% Stake Acquired
Board met on 28 Oct 2026 (04:30 p.m. to 04:56 p.m.) and approved unaudited standalone and consolidated results for Q2 and H1 FY27; the auditors' limited review report carries no modification.
By ScoutQuest · · 3 min read
- Revenue from operations (Q2 FY27)
- ₹ 813.75 million for the quarter vs ₹ 744.65 a year earlier; ₹ 1,696.07 million for the half year vs ₹ 1,500.77
- Profit for the period
- ₹ 125.90 million for the quarter vs ₹ 125.74; ₹ 257.79 million for the half year vs ₹ 233.69
- Basic EPS
- ₹ 1.91 for the quarter and ₹ 3.91 for the half year
What the board approved
The Board of Directors met on October 28, 2026 from 04:30 p.m. to 04:56 p.m. and considered and approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, along with the limited review report of the statutory auditors, Walker Chandiok & Co LLP.
- The review conclusion states that nothing has come to the auditors' attention that causes them to believe the statement has not disclosed the information required or that it contains any material misstatement. No qualification or adverse remark is recorded.
Standalone results (Rs. in million)
- Revenue from operations: 813.75 for the quarter ended September 30, 2026, against 744.65 in the same quarter a year earlier; 1,696.07 for the half year against 1,500.77.
- Total expenses: 665.43 for the quarter.
- Profit before tax: 168.28 for the quarter and 345.08 for the half year.
- Profit for the period: 125.90 for the quarter against 125.74; 257.79 for the half year against 233.69.
- Basic earnings per share: 1.91 for the quarter and 3.91 for the half year.
- Total equity: 2,438.01 as at September 30, 2026, against 2,761.72 as at March 31, 2026; total assets 2,954.24.
Auditor's note on the subsidiary
The consolidated review report states that the interim financial information of the subsidiary, Aequitas Healthcare Private Limited (subsidiary with effect from 01 July 2026), was reviewed by another auditor. That information reflects total assets of ₹ 212.33 million, total revenues of ₹ 151.28 million, total net loss after tax of ₹ (0.03) million and total comprehensive loss of ₹ (0.01) million for the quarter and year-to-date period ended September 30, 2026. The auditors state that their conclusion is not modified on this account.
Other actions during the quarter
- 120,000 stock options granted under the Employee Stock Option Plan 2022, and 223,775 equity shares allotted on exercise of vested stock options by eligible employees.
- Final dividend of ₹ 4 per equity share of face value ₹ 2, totalling ₹ 263.83 million for the year ended March 31, 2026, paid after shareholders' approval at the Annual General Meeting held on September 18, 2026.
- Acquisition of an 85% equity stake in Aequitas Healthcare Private Limited for a consideration of ₹ 208 million, with effect from July 1, 2026; transaction-related services of ₹ 2.35 million are shown as an exceptional item.
- Business Transfer Agreement dated September 23, 2026 with Group Pharmaceuticals Limited for the acquisition of the Wellness Portfolio on a going-concern basis by way of slump sale; closing formalities, including conditions precedent, were completed in October 2026, so there was no impact on the results for the quarter ended September 30, 2026.
Cash flow points (standalone, half year)
- Net cash flows from operating activities: 261.93 (Rs. in million); profit before tax 345.08.
- Buyback of equity shares including related expenses: 401.14.
- Dividend paid: 263.83.
- Cash and cash equivalents at the end of the period: 190.93.
What the update records
Approval of the quarterly and half-yearly results with an unmodified review conclusion, employee share allotments, a dividend payout completed during the quarter, and two acquisition-related transactions.
Also from Jagsonpal Pharmaceuticals
Q2 FY27 call: management expects quarterly revenue to cross INR100 crore in Q3, keeps INR500 crore FY28 vision
3 Nov 2026
Audio recording of Jagsonpal Pharmaceuticals Q2 FY27 earnings conference call held October 29, 2026 posted on website
29 Oct 2026
Jagsonpal Q2FY27 consolidated revenue up 29% to ₹964 Mn as Aequitas consolidates; reiterates ₹5,000 Mn Mission 2028
28 Oct 2026
More numbers
- Standalone Revenue from operations, Q2 FY27 (Rs. in Million)813.75 (Rs. in Million)
- Standalone Revenue from operations, Q2 FY26 (Rs. in Million)744.65 (Rs. in Million)
- Standalone Profit for the period, Q2 FY27 (Rs. in Million)125.90 (Rs. in Million)
- Standalone Profit for the period, H1 FY27 (Rs. in Million)257.79 (Rs. in Million)
- Final dividend per equity share of face value ₹ 2₹ 4
- Final dividend amount paid for FY ended 31 March 2026₹ 263.83 million
- Consideration paid for 85% equity stake in Aequitas Healthcare₹ 208 million
- Equity shares allotted on exercise of vested stock options223,775
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.